Skip to main content
Fig. 7 | Radiation Oncology

Fig. 7

From: The in vitro immunogenic potential of caspase-3 proficient breast cancer cells with basal low immunogenicity is increased by hypofractionated irradiation

Fig. 7

Impact of caspase inhibition on HMGB1 and Hsp70 release by MDA-MB231 breast cancer cells after hypofractionated irradiation and/or hyperthermia. MDA-MB231 breast cancer cells were treated with hypofractionated irradiation (4x4Gy or 6x3Gy) and/or hyperthermia (41,5 °C for 1 h). Ionizing irradiation was applied 4 h before or after hyperthermia on the first and last day of fractionation. The pan-caspase inhibitor zVAD-fmk was added to the cell cultures in a concentration of 50 μM at day one and three or four during hypofractionated irradiation with 4x4Gy or 6x3Gy, respectively. 24 h after the last treatment, supernatants were analyzed for the amount of extracellular HMGB1 (a) and Hsp 70 (b). Representative data of one out of two experiments, each performed at least in triplicates, are presented as mean ± SD. Gy: Gray; HT: hyperthermia; HMGB1: high mobility group box protein 1; Hsp70: heat shock protein 70; n.d.: not detectable; w/o: mock treated control; zVAD: pan caspase inhibitor zVAD-fmk. **p <0,01 compared to samples without zVAD

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us